Ignite Creation Date:
2024-05-06 @ 4:00 PM
Last Modification Date:
2024-10-26 @ 2:01 PM
Study NCT ID:
NCT04830345
Status:
COMPLETED
Last Update Posted:
2022-04-04
First Post:
2021-03-31
Brief Title:
Efficacy and Safety of Botulinum Toxin at Moderate to Severe Glabellar Lines
Sponsor:
EuBiologics CoLtd
Organization:
EuBiologics CoLtd
Study Overview
Official Title:
A Multicenter Double-blind Randomized Parallel Active-controlled Non-inferiority Phase 3 Clinical Trial to Compare the Efficacy and Safety of ATGC-100 Versus Botox in Subjects With Moderate to Severe Glabellar Lines
Status:
COMPLETED
Status Verified Date:
2021-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Efficacy and safety of ATGC-100 are assessed in subjects with moderate to severe glabellar lines
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None